Skip to content

Author

A. Saha

We have 3 of 32 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Impact of chronic obstructive pulmonary disease on survival after chimeric antigen receptor T-cell therapy in large B-cell lymphoma.

BACKGROUND Chimeric antigen receptor T-cell (CAR T-cell) therapy is the standard of care for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The impact of pre-existing chronic obstructive pulmonary disease (COPD) on outcomes of LBCL after CAR-T cell therapy are not well characterized. This study aimed at evalua...

M. Uyanik, Athanasios Tsalatsanis, I. Muhsen et al. · 0 citations
Sep 2026

B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Pirtobrutinib and CAR T-cell therapy and CAR T-cell therapy have emerged as effective treatment options for refractory or progressive disease after prior treatment with covalent BTK inhibitors.

A. Zelenetz, Leo I. Gordon, Jeremy S. Abramson et al. · 0 citations
Open access Jul 2026

A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.

TPFS6 remained prognostic for OS and PFS even after accounting for PD/SD, underscoring the impact of severe toxicity on subsequent survival, and may predict long-term outcomes following CAR-T therapy.

A. Saha, Junmin Whiting, R. Mohty et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.